All In Biotech

Drug Trial Radar · NCT02379572

Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas

Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

315

Actual

Start

Jun 2015

Primary completion

Jun 2020

Study completion Jul 1, 2021

Sponsor

Lead sponsor
University Hospital TuebingenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by concomitant chemoradiation. The extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. State of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer survival of patients might be possible. To date no comparison of these two leading technologies for GBM-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies. Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours after surgery) in each group. Secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival. The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers (n=13) to exclude possible bias which might be found by randomizing patients within individual iMRI centers and to have surgeons with the most experience possible in use of each respective technology.

Conditions

  • Glioblastoma

Interventions

  • iMRI-guided surgeryDevice

    For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.

  • 5-ALA-guided surgeryDrug

    For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete resections in the postoperative MRI (T1+/-CM) within 48 hours after surgeryTime frame: 48 hour

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany

    Bonn, Germany

  • Department of Neurosurgery, Universität zu Köln, Köln, Germany

    Cologne, Germany

  • Städtisches Klinikum Dresden Friedrichstadt

    Dresden, Germany

  • Department of Neurosurgery, Heinrich-Heine-Universität Düsseldorf, Düsseldorf

    Düsseldorf, Germany

  • Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nürnberg

    Erlangen, Germany

  • Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt am Main

    Frankfurt a.M., Germany

  • Department of Neurosurgery, Georg-August-Universität Göttingen, Göttingen,

    Göttingen, Germany

  • Department of Neurosurgery, University of Ulm, Hospital Günzburg,

    Günzburg, Germany

  • Asklepios Klinik Hamburg, Klinik für Neurochirurgie

    Hamburg, Germany

  • International Neuroscience Institute Hannover, Hannover, Germany

    Hanover, Germany

  • Department of Neurosurgery, Ruprecht-Karls-University Heidelberg

    Heidelberg, Germany

  • Department of Neurosurgery, University of Schleswig-Holstein, Kiel, Germany

    Kiel, Germany

  • Department of Neurosurgery, Westfälische Wilhelms-Universität Münster, Münster, Germany

    Münster, Germany

  • Department of Neurosurgery, Eberhard Karls University, Tübingen,

    Tübingen, Germany

  • Department of Neurosurgery, Julius-Maximilians-Universität Würzburg

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.